NDAORALTABLET
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
TRULANCE (plecanatide) by Salix Pharmaceuticals is guanylate cyclase activators [moa]. First approved in 2017.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRULANCE (plecanatide) is an oral guanylate cyclase-C agonist approved in 2017 for chronic idiopathic constipation. It works by activating GC-C receptors on intestinal epithelial cells to increase fluid secretion and promote bowel movements. This mechanism represents a distinct approach within the constipation treatment landscape.
$0.119BPart D
Peak8.0 years to LOEProduct is at peak sales with stable Medicare utilization; teams likely optimized for defending market position against emerging competitors.
Mechanism of Action
Guanylate Cyclase Activators
Pharmacologic Class:
Guanylate Cyclase-C Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
Started Mar 2022
648 enrolled
Functional Constipation
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
Started Jun 2018
218 enrolled
Irritable Bowel Syndrome With Constipation
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
Started Jun 2018
7 enrolled
Chronic Idiopathic Constipation
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
Started Jan 2017
124 enrolled
Chronic Idiopathic Constipation
Long Term Safety Study of Plecanatide
Started Jan 2016
2,272 enrolled
Irritable Bowel Syndrome
Worked on TRULANCE at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.